we provided evidence that PMF patients have a relevant and life-threatening risk of thrombosis and that the lower-risk IPSS categories (low/intermediate-1) harboring the JAK2 V617F mutation are at the highest risk. In clinical practice, this risk could justify studies testing primary prophylaxis with low-dose aspirin in all positive JAK2 V617F patients, particularly in those with lower-risk IPSS scores, if not otherwise contraindicated.

Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score

Rumi E;Vanni D;Borsani O;
2022-01-01

Abstract

we provided evidence that PMF patients have a relevant and life-threatening risk of thrombosis and that the lower-risk IPSS categories (low/intermediate-1) harboring the JAK2 V617F mutation are at the highest risk. In clinical practice, this risk could justify studies testing primary prophylaxis with low-dose aspirin in all positive JAK2 V617F patients, particularly in those with lower-risk IPSS scores, if not otherwise contraindicated.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11571/1477523
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 7
social impact